Sargent Bickham Lagudis’s GSK GSK Stock Holding History

Sargent Bickham Lagudis’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-182	Closed	-$9K	–	784
2020 Q1	$9K	Hold	182	–	–	﹤0.01%	566
2019 Q4	$11K	Hold	182	–	–	﹤0.01%	603
2019 Q3	$10K	Hold	182	–	–	﹤0.01%	561
2019 Q2	$9K	Sell	182 -421	-70%	-$21.1K	﹤0.01%	599
2019 Q1	$32K	Sell	603 -77	-11%	-$3.85K	﹤0.01%	449
2018 Q4	$32K	Buy	680 +188	+38%	+$9.26K	﹤0.01%	422
2018 Q3	$25K	Buy	492 +6	+1%	+$305	﹤0.01%	460
2018 Q2	$25K	Buy	486 +6	+1%	+$302	﹤0.01%	458
2018 Q1	$23K	Buy	480 +400	+500%	+$18.6K	﹤0.01%	458
2017 Q4	$4K	Sell	80 -400	-83%	-$18.5K	﹤0.01%	699
2017 Q3	$24K	Hold	480	–	–	﹤0.01%	471
2017 Q2	$26K	Hold	480	–	–	﹤0.01%	446
2017 Q1	$25K	Hold	480	–	–	﹤0.01%	456
2016 Q4	$23K	Sell	480 -299	-38%	-$14.8K	﹤0.01%	443
2016 Q3	$42	Buy	779 +193	+33%	+$10.6K	0.01%	375
2016 Q2	$32K	Buy	586 +312	+114%	+$16.4K	0.01%	397
2016 Q1	$14K	Buy	+274	New	+$13.6K	﹤0.01%	523

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sargent Bickham Lagudis's GSK Position: Q2 2020 in Review

Sargent Bickham Lagudis sold out of GSK (GSK) in Q2 2020, closing a stake of 182 shares — an estimated $9K sold.

Sargent Bickham Lagudis first reported a position in GSK in Q1 2016 and held it in 17 quarters. The position peaked at $32K in Q1 2019. 840 funds tracked by Wall St. Rank hold GSK as of Q2 2020.

Sargent Bickham Lagudis reported no remaining GSK position as of Q2 2020 after selling out during the quarter.
Sargent Bickham Lagudis sold 182 GSK shares in Q2 2020, an estimated $9K.
Sargent Bickham Lagudis first reported a position in GSK in Q1 2016 and held it in 17 quarters.
Sargent Bickham Lagudis's GSK position peaked at $32K in Q1 2019.
840 funds tracked by Wall St. Rank held GSK as of Q2 2020.

Based on Sargent Bickham Lagudis's 13F filing for Q2 2020, filed 7 Sep 2021.